The Vox Markets Podcast cover art

The Vox Markets Podcast

The Vox Markets Podcast

By: Vox Markets Podcast
Listen for free

About this listen

Vox Markets is revolutionising the way companies engage with all classes of shareholders. Listen here to interviews with company executives and sell-side analysts and fund managers discuss their investment insights.Vox Markets Economics Personal Finance
Episodes
  • 2379: 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott
    Apr 24 2026

    On today’s live Vox Markets smallcap show, I discussed my latest thoughts on 20 stock ideas. Unfortunately though UK equity analyst & markets commentator Paul Scott (who apologises profusely) was feeling ill so couldn’t join this week. Everything though should back to normal service next Thursday 30th April at 2pm.

    02:25 Advanced Medical Solutions
    04:40 BRCK / Brickability
    07:00 Inspiration Healthcare
    10:10 ONDO Insurtech
    11:20 Restore
    13:10 Computacentre
    15:50 Domino’s Pizza
    17:40 Goodwin
    21:00 hVivo
    24:10 Cerillion
    26:40 Ensilica
    29:15 Spire Healthcare
    32:25 WISE
    34:25 Tracsis
    37:45 Saas-apocalypse impact on software, RELX & Experian
    42:45 Hikma Pharmaceuticals
    46:35 NWF
    49:25 CVS Group
    52:30 Supreme
    54:25 System1
    57:20 Carclo

    Show More Show Less
    1 hr and 2 mins
  • 2378: Why Is the Market Ignoring Zinc Media?
    Apr 24 2026

    Watch on YouTube

    Zinc Media AIM: ZIN) CEO Mark Browning sits down with Vox Markets to unpack five consecutive years of growth across the group’s key profit metrics, the rapid rise of higher-margin IP revenues, a step-change in Middle East earnings, and two fresh catalysts — a new CCO appointment and the recommission of Celebrity Inner Circle. With forward revenue visibility building and a share price yet to reflect the P&L, the conversation probes why the market may still be underestimating this quietly compounding content group.

    Show More Show Less
    22 mins
  • 2377: hVIVO Lands Landmark Phase III Trial
    Apr 22 2026
    hVIVO has been selected to run the world’s first pivotal Phase III human challenge trial in whooping cough, marking a major scientific milestone and its largest study to date. The contract strengthens revenue visibility into 2026–27 while underlining the growing importance of human challenge trials in accelerating vaccine approvals globally.
    Show More Show Less
    7 mins
No reviews yet